We present here the first evidence that granzyme B acts against Plasmodium falciparum (50% inhibitory concentration [IC 50 ], 1,590 nM; 95% confidence interval [95% CI], 1,197 to 2,112 nM). We created a novel antimalarial fusion protein consisting of granzyme B fused to a merozoite surface protein 4 (MSP4)-specific single-chain Fv protein (scFv), which targets the enzyme to infected erythrocytes, with up to an 8-fold reduction in the IC 50 (176 nM; 95% CI, 154 to 202 nM). This study confirms the therapeutic efficacies of recombinant antibody-mediated antimalarial immunotherapeutics based on granzyme B. Citation Kapelski S, de Almeida M, Fischer R, Barth S, Fendel R. 2015. Antimalarial activity of granzyme B and its targeted delivery by a granzyme B-single-chain Fv fusion protein. Antimicrob Agents Chemother 59:669 -672.
M alaria is caused by parasites of the genus Plasmodium and remains one of the most widespread and dangerous infectious diseases, causing ϳ627,000 deaths worldwide per year (1) . Among the six species that infect humans, Plasmodium falciparum causes the severest form of the disease (2) . There is no effective vaccine against these parasites (3, 4) , and resistances are emerging against a wide variety of antimalarial drugs (5) . It was recently shown in vitro that natural killer (NK) cells can eliminate erythrocytes infected with P. falciparum (6) and that this is associated with the production of the serine protease granzyme B (Gb) (7) . In vivo, NK cells are essential for protection against plasmodial infections in mice (8) , and increased levels of circulating Gb are found in naturally infected humans (9) .
We therefore investigated the antimalarial effect of recombinant Gb on P. falciparum (strain 3D7A) in a standardized 72-h drug susceptibility assay starting with synchronized ring-stage parasites (10) . Gb was produced in HEK293 cells with an N-terminal protective peptide fused to an enterokinase cleavage site (EGb) to suppress the enzymatic activity in the host cells, as previously described (11) . Activity was restored by the enzymatic removal of this peptide using 0.02 U of recombinant enterokinase (Novagen; Merck) per g of protein (12) . The restored enzymatic activity was confirmed using a colorimetric activity assay (13) . Parasite growth was specifically inhibited by activated Gb, with a half-maximal inhibitory concentration (IC 50 ) of 1,590 nM (95% confidence interval [95% CI], 1,197 to 2,112 nM, calculated using the Hill equation in GraphPad Prism version 5). Undigested (inactive) EGb showed no inhibition ( Fig. 1 and Table 1 ). To our knowledge, this is the first time that the antimalarial activity of Gb has been directly confirmed in vitro.
We developed a strategy to target Gb to the parasite and thus reduce the required dose. Targeted toxin delivery via the parasite transferrin receptor has already been reported (14, 15) . Although some authors claim to have identified and characterized this receptor (16, 17) , others argue that iron uptake by the parasite is nonspecific and that the P. falciparum transferrin receptor remains elusive (18) . Promising alternative targets include the merozoite surface proteins (MSPs), especially MSP1, MSP2, MSP4, and MSP8, which bear glycosylphosphatidylinositol (GPI) anchors and therefore are not completely shed during merozoite invasion. Some also contain immunogenic epidermal growth fac-tor (EGF)-like domains near the C-terminal GPI anchors, which serve as ideal targets for specific antibodies (19) (20) (21) (22) . Because EGFlike domains are less variable between strains and even species (23), they are ideal targets for antibody-based approaches. Recently, it was shown that MSP4 is imported into newly infected erythrocytes without significant processing, and it remains there for up to 5 h (24). MSP4-specific antibodies or their fragments are therefore attractive candidates for guiding Gb into the infected erythrocyte.
We generated a single-chain variable fragment (scFv) from an MSP4 EGF-like domain -specific murine antibody, 2.44IgG1 (S. Kapelski, A. Boes, H. Spiegel, M. de Almeida, T. Klockenbring, A.
Reimann, R. Fischer, S. Barth, and R. Fendel, unpublished data), by splicing by overlap extension (SOE)-PCR using a glycine-serine linker peptide and fusing it to the SerpinB9-resistant EGb R201K mutant (12) . This was expressed in HEK293-6E cells using a vector based on pTT5 (25) modified with an expression cassette designed for EGb-scFv fusion proteins (26, 27) . Two unrelated EGb-scFv fusion constructs named EGb-H22 (targeting human CD64) (11) and EGb-Ki4 (targeting human CD30) (13) were used as negative controls. Following enterokinase-mediated activation, the Gb-scFv fusion proteins were used in a 48-h drug susceptibility assay, similar to the standard invasion inhibition assay used for the evaluation of antibodies (28) . We also used 2.44IgG1 as a full-size control antibody in the assay. The proteins were added to syn-chronous schizont-stage P. falciparum 3D7A parasites growing in 96-well half-area microtiter cell culture plates at a parasitemia level of 0.05% and a final hematocrit level of 1.5%, in a total volume of 50 l per well. After incubation for 48 h, inhibition was determined as described previously (29) . The IC 50 of Gb-2.44 was 176 nM (95% CI, 154 to 202 nM), which was 5-to 8-fold lower than that of Gb, Gb-H22, and Gb-Ki4, each of which showed IC 50 s of ϳ1,000 nM ( Fig. 2A and Table 1 ). Undigested controls (EGb-2.44, EGb-H22, EGb-Ki4, and EGb) and antibody 2.44IgG1 showed no effect on parasite growth (Table 1) . Similar experiments were carried out using the multidrug-resistant strain P. falciparum K1, resulting in a similar IC 50 for Gb-2.44, which were again substantially lower than that of Gb-Ki4 and of Gb-H22 ( Fig. 2B and Table 1 ). The various fusion partners of the Gb constructs might have an influence on enzymatic activity. Therefore, the enzymatic activity of each construct was determined by a colorimetric assay (13) , and the relative activity to Gb-2.44 was calculated. All IC 50 s were corrected by this factor ( Table 1) .
The dependency of the enhanced inhibition of parasite growth was assessed in a 30-h drug susceptibility assay. Here, the fusion proteins were added to synchronous ring-stage parasites at a 0.2% parasitemia level (to achieve an equal parasitemia level at the assay endpoint in the wells without any parasite inhibition) and 1.5% hematocrit and incubated until mature schizonts were present, omitting a schizont rupture and merozoite invasion step. Thus, without possible coimport of the P. falciparum-specific Gb-2.44 into the newly infected erythrocyte along with the merozoite, the Gb fusion proteins all showed similar levels of inhibition ( Fig. 3 and Table 1 ).
Of note, the IC 50 s determined in the various assays are not equivalent, as the drug exposure time of the parasites has a direct influence on the IC 50 . Therefore, we strictly perform intra-assay comparisons of IC 50 s.
We have therefore provided direct confirmation that Gb has antiparasitic activity, and we demonstrated its potential therapeutic use against malarial infections. The concept of recombinant immunotoxins has been extensively investigated in the field of targeted tumor therapy with various bacterial and human effector domains (30) (31) (32) , including Gb (11, 13, 27, 33) . After binding to a disease-specific cell surface antigen, these immunotoxins are internalized, e.g., by receptor-mediated endocytosis, released from endosomal compartments into the cytoplasm, and efficiently kill the malignant cell by their catalytic activity. In the case of Gb, the corresponding human cytolytic fusion protein proteolytically cleaves certain caspases to induce apoptosis (34) . Comparably, P. falciparum bears one designated metacaspase, P. falciparum MCA-1 (35) , which may be the target of Gb. Another hypothesis is that Gb induces eryptosis in infected erythrocytes and thus kills the parasite (7) .
Taken together, we provide solid evidence that Gb-containing malaria-specific fusion proteins are valuable drug candidates acting against multidrug-resistant P. falciparum strains. The IC 50 of these novel immunotherapeutic agents in the drug susceptibility assay lies within the range for a hit candidate as a new therapeutic agent, as suggested by the Medicines for Malaria Venture (MMV) (http://www.mmv.org/research-development/essential-information -scientists). The 50% effective concentration [EC 50 ] of recombinant Gb in vitro (using Jurkat cells) is ϳ8 M (36); thus, the estimated selectivity index of our human antimalarial fusion protein is Ͼ40.
In further studies, we will investigate the underlying mechanism of its antimalarial activity in order to increase the specificity and further reduce the inhibitory concentration.
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